Research and development

mRNA
#mRNA #Research and development #RNA sequencing #Takara Bio

New product could aid successful production of mRNA therapeutics

Takara Bio has launched PrimeCap T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development. PrimeCap T7 RNA Polymerase is a mutant T7 RNA polymerase that has been genetically engineered to maintain high-performance RNA synthesis activity while reducing dsRNA… Read More

#News

#Chiesi #Collaboration #Karolinska Institutet #Research and development

Collaboration to make therapeutic solutions to health challenges

Chiesi Group has signed a memorandum of understanding with Karolinska Institutet (KI) to collaborate on joint efforts aimed accelerating research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications. Chiesi Group and KI will exchange ideas, expertise, and resources… Read More

#News

#Bill & Melinda Gates Foundation #Charity #Investment #LMICs #Research and development #Wellcome Trust

Industry philanthropists accelerate global health and equity impact

The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation have announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Clinical research
#Drug discovery #LifeArc #Rare disease #Research and development

LifeArc’s £40m research centres to boost research into rare diseases

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. The virtual centres will focus on areas where there are significant unmet needs. They aim to tackle barriers that ordinarily prevent… Read More

#News

AI brain
#Artificial intelligence (AI) #EFPIA #Europe #Regulatory #Research and development

EFPIA states AI rules must “enable not hinder” pharma R&D

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act. The AI Act, which bans certain AI applications that it… Read More

#Editor's Choice #News

Gilead Sciences, Oxford facility
#Acute inflammatory conditions #Gilead Sciences #MiroBio #Research and development #UK

Gilead Sciences opens first research centre outside US

Gilead Sciences has opened a new research site at the Business Park in Oxford, UK. With capacity for up to 60 research scientists and employees, the company says the site will play a role in helping to drive innovation in the UK life sciences sector, with… Read More

#News

#ENA Respiratory #Funding #Research and development

Government funding for Phase II respiratory infection programme 

Australian clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the US Department of Defense (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.   The new… Read More

#Business & Investment #News #Regulatory

#Career #Interview #Meet the Researcher #Research and development

Meet the researcher: Giusy Di Conza, iOnctura

Listen to this article on the DDW Podcast: DDW’s Megan Thomas looks at a day in the life of Giusy Di Conza, Head of Research at iOnctura. MT: Where do you work, and can you tell us what you’re working on at the moment? GDC: I’m Head of Research for a… Read More

#Exclusive Content

#Drug discovery #Research #Research and development

Scientific SaaS platform to accelerate drug and materials development 

Revvity has launched its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.   The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the… Read More

#News